

Technical Report No. 14
Revised 2008
Validation of Column-
Based Chromatography
Processes for the
Purification of Proteins

PDA Journal of
Pharmaceutical
Science and
Technology

2008

Supplement

Volume 62

No. S-3



Validation of Column-Based Chromatography Processes for the Purification of Proteins Task Force

E.J. Brandreth, formerly with Favville, Inc.

Chris Bussineau, PhD, BioVascular, Inc.

Michelle Butler, Genentech, Inc.

Tony Christensen, Scantago ApS

Doris Conrad, Conrad Associates

Becky Devine, Independent Regulatory Consultant

Ranga Godavarti, PhD, Wyeth BioPharma

Eric Grund, PhD, GE Healthcare

Norbert Hentschel, Boehringer Ingelheim Pharma GmbH & Co KG

Philip Lester, Genentech, Inc.

Jennifer McNay, Regeneron Pharmaceuticals Inc.

Michael Muegge, Bayer Healthcare Corporation

Stephen Notarnicola, PhD, Biogen Idec, Inc.

Rahul Patel, Immunomedics, Inc.

Anurag Rathore, PhD, Amgen, Inc.

Laurie Scaggs, formerly with Abbott Laboratories

The content and views expressed in this technical report are the result of a consensus achieved by the authoring task force and are not necessarily views of the organizations they represent.

Validation of Column-Based Chromatography Processes for the Purification of Proteins

Technical Report No. 14

**Supplement to the
*PDA Journal of Pharmaceutical
Science and Technology***

Vol 62, No. S-3

2008

© 2008 PDA



Table of Contents

1.0 INTRODUCTION	2
1.1 Purpose/Scope	2
2.0 GLOSSARY OF TERMS	4
3.0 CHROMATOGRAPHY VALIDATION PREREQUISITES	8
3.1 Process Risk Assessment	8
3.2 Materials	9
3.3 Process Characterization	9
3.3.1 Scale-Down Model	10
3.3.2 Identification and Classification of Operational Parameters	10
3.3.3 Process Robustness	11
3.4 Analytical Methods	13
3.5 Bioburden and Endotoxin Control	13
3.6 Development and Characterization Documentation	13
4.0 COLUMN PROCESS VALIDATION	14
4.1 Conformance Batches: Production-Scale Validation.....	14
4.1.1 Control of Operational Parameters	15
4.1.2 Monitoring Column Performance	16
4.1.3 Reduction of Impurities.....	16
4.1.4 Bioburden and Endotoxin Control.....	16
4.2 Small-Scale Validation Studies	16
4.2.1 Viral Clearance Studies.....	17
4.2.2 Resin Lifetime Studies	18
4.2.2.1 Column Cleaning and Regeneration ...	19
4.2.2.2 Storage	19
4.2.2.3 Process-Related Impurities	20
4.3 Validation Documentation.....	20
4.3.1 Protocols and Reports.....	21
5.0 POST-VALIDATION ACTIVITIES	22
5.1 Ongoing Monitoring and Maintenance	22
5.2 Change Control.....	22
6.0 SUMMARY	23
7.0 APPENDICES	24
7.1 Types of Chromatography.....	24
7.2 Experimental Design.....	25
7.3 Raw Materials (Resin and Non-Resin)	26
7.3.1 Selection and Performance of Resins.....	27
7.3.2 Establishing Resin Specifications	27
7.3.3 Resin Leachables and Ligand Concerns..	28
7.3.4 Resin Shelf Life	28
7.3.5 Non-Resin Raw Materials	28
7.4 Equipment	29
7.4.1 User Requirement Specification (URS) and Design Qualification (DQ)	29
7.4.2 Commissioning	29
7.4.3 Installation Qualification (IQ).....	30
7.4.4 Operational Qualification (OQ).....	31
7.4.5 Performance Qualification (PQ)	32
7.5 Column Packing and Testing.....	32
8.0 REFERENCES	35